Patents by Inventor Juan Manuel Decara Del Olmo

Juan Manuel Decara Del Olmo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITION FOR PREVENTING AND TREATING TAUOPATHIES
    Publication number: 20220313620
    Abstract: This invention relates to the delivery of a composition, preferably a pharmaceutical composition, comprising D-pinitol, D-Chiro inositol or myo-inositol or any pharmaceutically acceptable salt thereof, for use in the treatment or prevention of disorders, diseases or conditions responsive to the stimulation of the ghrelin receptor in a subject in need thereof.
    Type: Application
    Filed: September 9, 2020
    Publication date: October 6, 2022
    Inventors: Fernando RODRIGUEZ DE FONSECA, Juan Antonio NAVARRO GALERA, Elena BAIXERAS LLANO, Juan Manuel DECARA DEL OLMO, Dina MEDINA VERA, Antonio Jesús LÓPEZ GAMBERO, Juan SUAREZ PEREZ, Carlos SANJUAN MERINO, Cristina ROSELL DEL VALLE, Francisco Javier PAVÓN MORÓN
  • Fatty acid amides for the prevention and/or treatment of steatohepatitis
    Patent number: 11058650
    Abstract: The invention relates to the use of fatty acid amides with phenylalkylamines and of a pharmaceutical composition comprising at least one of these compounds in the prevention and/or treatment of fatty liver or a pathological condition or disease caused by fatty liver, either alcoholic or non-alcoholic, and, in particular, for the prevention and/or treatment of the alcoholic steatohepatitis or non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: July 13, 2021
    Assignees: FUNDACIÓN PÚBLICA ANDALUZA PARA LA INVESTIGACIÓN DE MÁLAGA EN BIOMEDICINA Y SALUD (FIMABIS), CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), FUNDACIÓ INSTITUT MAR DTNVESTIGACIONS MÈDIOUES
    Inventors: Fernando Rodríguez De Fonseca, Francisco Javier Pavón Morón, Juan Manuel Decara Del Olmo, Antonia Serrano Criado, Jesús Joglar Tamargo, Pedro Clapés Saborit, Rafael De La Torre Fornell, Magí Ferre Albaladejo, María Isabel Covas Planells, Montserrat Fito Colomer, Bruno Almeida Cotrim
  • FATTY ACID AMIDES FOR THE PREVENTION AND/OR TREATMENT OF STEATOHEPATITIS
    Publication number: 20180193293
    Abstract: The invention relates to the use of fatty acid amides with phenylalkylamines and of a pharmaceutical composition comprising at least one of these compounds in the prevention and/or treatment of fatty liver or a pathological condition or disease caused by fatty liver, either alcoholic or non-alcoholic, and, in particular, for the prevention and/or treatment of the alcoholic steatohepatitis or non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: November 24, 2015
    Publication date: July 12, 2018
    Inventors: Fernando RODRÍGUEZ DE FONSECA, Francisco Javier PAVÓN MORÓN, Juan Manuel DECARA DEL OLMO, Antonia SERRANO CRIADO, Jesús JOGLAR TAMARGO, Pedro CLAPÉS SABORIT, Rafael DE LA TORRE FORNELL, Magí FERRÉ ALBALADEJO, María Isabel COVAS PLANELLS, Montserrat FITO COLOMER, Bruno ALMEIDA COTRIM
  • 1,2,4-oxadiazole derivatives as drugs modulating the GLP-1 peptide receptor
    Patent number: 9050347
    Abstract: The present invention relates to the use of a compound of formula (I): or a pharmaceutically acceptable solvate or salt thereof in the preparation of a medicinal product for the prevention and/or the treatment of a disease in which the GLP-1 receptor participates or mediates, such as eating disorders or diseases, for example, obesity, anorexia, lipid dysfunction, diabetes, hyperinsulinism and cardiovascular diseases or metabolic syndrome.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: June 9, 2015
    Assignee: VIVIABIOTECH, S.L.
    Inventors: Fernando Antonio Rodríguez De Fonseca, Miguel Romero Cuevas, Laura Orio Ortíz, Juan Manuel Decara Del Olmo, Monica Alonso Scrignoli
  • 1,2,4-OXADIAZOLE DERIVATIVES AS DRUGS MODULATING THE GLP-1 PEPTIDE RECEPTOR
    Publication number: 20140031347
    Abstract: The present invention relates to the use of a compound of formula (I): or a pharmaceutically acceptable solvate or salt thereof in the preparation of a medicinal product for the prevention and/or the treatment of a disease in which the GLP-1 receptor participates or mediates, such as eating disorders or diseases, for example, obesity, anorexia, lipid dysfunction, diabetes, hyperinsulinism and cardiovascular diseases or metabolic syndrome.
    Type: Application
    Filed: January 25, 2011
    Publication date: January 30, 2014
    Applicant: VIVIABIOTECH, S.L.
    Inventors: Fernando Antonio Rodríguez De Fonseca, Miguel Romero Cuevas, Laura Orio Ortiz, Juan Manuel Decara Del Olmo, Monica Alonso
  • HYDROXYTYROSOL ETHERS
    Publication number: 20130267588
    Abstract: The invention relates to hydroxytyrosol ethers derived from fatty alcohols and phenolic compounds of olive oil and the salts, solvates and hydrates thereof, which have an affinity for type 1 cannabinoid receptors (CB1) and which can: prevent the oxidation of low-density lipoprotein (LDL); and modulate the actions regulated by said receptor, such as inducing satiety, controlling intake and reducing body fat.
    Type: Application
    Filed: December 19, 2011
    Publication date: October 10, 2013
    Applicants: FUNDACIO IMIM, FUNDACION INSTITUTO MEDITERRANEO PARA EL AVANCE DE LA BIOTECNOLOGIA Y LA INVESTIGACION SANITARIA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
    Inventors: Rafael De La Torre Fornell, Magin Farre Albaladejo, Maria Isabel Covas Planells, Montserrat Fito Colomer, Bruno Almeida Cotrim, Fernando Rodriguez De Fonseca, Juan Manuel Decara Del Olmo, Miguel Romero Cuevas, Jesus Joglar Tamargo, Pedro Clapes Saborit